Biosimilar Lawsuit Highlights AJPB Week in Review

From AKI dosing to CKM therapeutic inertia, experts at ASN Kidney Week 2026 pointed to pharmacists as key to moving new kidney data into practice.

From insurance delays to injection concerns, pharmacists can help patients navigate the first month and avoid preventable treatment interruptions.

Jai Radhakrishnan, MD, MBBS, MS, FASN, discusses why IgG4-related kidney disease is often missed and what the MITIGATE subgroup data presented at ASN Kidney Week 2026 show.

Before lung cancer therapy begins, diagnostic findings and treatment readiness shape care, creating opportunities for pharmacists to help patients start safely.

October’s pain management coverage examined postoperative suzetrigine, pharmacist follow-up for cancer-related neuropathic pain, constipation prevention, and counseling patients concerned about prescribed opioids.

CDC surveillance data show that approximately 10% of adults hospitalized with RSV died during hospitalization or within 60 days of discharge.

VAX-31 met all primary immunogenicity end points against PCV20 and PCV21 in the pivotal OPUS-1 trial.

October’s hematology coverage highlighted first-line pirtobrutinib, questions about myeloma treatment duration and early intervention, and pharmacists’ roles in medication safety and access.